BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS

American Journal of Hematology

Volumn 89, Issue 5, 2014, Pages 499-504

  Zhang, Liping ^a   Singh, Rajesh R ^a   Patel, Keyur P ^a   Stingo, Francesco ^a   Routbort, Mark ^a   You, M James ^a   Miranda, Roberto N ^a   Garcia Manero, Guillermo ^a   Kantarjian, Hagop M ^a   Medeiros, L Jeffrey ^a   Luthra, Rajyalakshmi ^a   Khoury, Joseph D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD135 ANTIGEN; ISOCITRATE DEHYDROGENASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOPHOSMIN; PROTEIN KINASE LKB1; PROTEIN P53; RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CODON; CYTOGENETICS; DNA BINDING; EXON; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84898489137     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23652     Document Type: Article

References (46)

1. Orazi A, Bennett JM, Germing U, et al. Chronic myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp 76-79.
2. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
3. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:610-619.
4. Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367:2316-2321.
5. Wang J, Liu Y, Li Z, et al. Endogenous oncogenic NRAS mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. Blood 2011;118:368-379.
6. Wang J, Liu Y, Li Z, et al. Endogenous oncogenic NRAS mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010;116:5991-6002.
7. Wang J, Kong G, Liu Y, et al. NRAS G12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions. Blood 2013;121:5203-5207.
8. Braun BS, Archard JA, Van Ziffle JA, et al. Somatic activation of a conditional KRAS G12D allele causes ineffective erythropoiesis in vivo. Blood 2006;108:2041-2044.
9. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-774.
10. Roring M, Herr R, Fiala GJ, et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012;31:2629-2647.
11. An L, Jia W, Yu Y, et al. Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling. Sci Rep 2013;3:2344.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
13. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308.
14. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
15. Kar SA, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 2013;98:107-113.
16. Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011;118:3932-3941.
17. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013;121:2186-2198.
18. Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic KRAS in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:597-602.
19. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006;108:2349-2357.
20. Li Q, Haigis KM, McDaniel A, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NRASG12D from the endogenous locus. Blood 2011;117:2022-2032.
21. Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013;501:232-236.
22. Zuo Z, Chen SS, Chandra PK, et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009;22:1023-1031.
23. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-849.
24. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-383.
25. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
26. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
27. Abdel-Wahab O, Kilpivaara O, Patel J, et al. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010;24:1656-1657.
28. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
29. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood 2009;113:1749-1755.
30. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012;209:1537-1551.
31. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-263.
32. Ashur-Fabian O, Adamsky K, Trakhtenbrot L, et al. APAF1 in chronic myelogenous leukemia (CML) progression: reduced APAF1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle 2007;6:589-594.
33. Solomon H, Buganim Y, Kogan-Sakin I, et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci 2012;125:3144-3152.
34. Hou P, Liu D, Xing M. The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. Leukemia 2007;21:2216-2218.
35. Kamata T, Hussain J, Giblett S, et al. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 2010;70:8475-8486.
36. Gustafsson B, Angelini S, Sander B, et al. Mutations in the BRAF and N-RAS genes in childhood acute lymphoblastic leukaemia. Leukemia 2005;19:310-312.
37. Garnett MJ, Rana S, Paterson H, et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963-969.
38. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
39. Board RE, Ellison G, Orr MC, et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009;101:1724-1730.
40. Suehiro Y, Wong CW, Chirieac LR, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res 2008;14:2560-2569.
41. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-187.
42. Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38-43.
43. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-810.
44. Liu W, Monahan KB, Pfefferle AD, et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012;21:751-764.
45. Zheng B, Jeong JH, Asara JM, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009;33:237-247.
46. Su F, Bradley WD, Wang Q, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012;72:969-978.